Anna Frostegård is a globally educated, board-certified physician holding MD summa cum laude. She obtained her PhD in Experimental Medicine at Karolinska Institutet, Stockholm, Sweden. Dr. Frostegård served as Assistant Professor at the Unit of Immunology and Chronic Disease at Karolinska Institutet. Anna’s areas of expertise include inflammation & immunology, autoimmunity, cardiovascular, ophthalmology and infection. She has an active career in both science and business. Dr. Frostegård has over 15 years of “first hand” entrepreneurial, strategic and operational leadership in biotech, translating academic inventions into new companies and drug development processes, a true from “bench to patients” experience. Anna has wide experience in building biotech companies, intellectual property portfolios, in- and out-licensing, financing (private and public).
She is the inventor, co-founder and currently the Chief Scientific and Medical Officer in Annexin Pharmaceuticals AB (publ). She carries the key strategic responsibilities for R&D, business development, scientific and clinical due dilligence, international academic-industry collaborations and financing. She is the co-inventor on several granted patents and pending applications related to the therapeutic use of Annexin A5, an endogenous protein with anti-inflammatory properties and holds several awards for scientific communication.
She has co-founded 5 companies within the EU. She serves as a board member in several private life science/biotech companies. She consults on effective interactions between academic inventors and biotechnology industry. She analyses and advises on early/pre-clinical stage investments in biotechnology.
Anna had been living, studying and working in different cultures and environments including USA, Austria, Sweden, Russia and Czech Republic.